Phaseline

Targets › PDCD1LG1

PDCD1LG1 (Programmed cell death 1 ligand 1): drug programs, companies and trials

12 programs from 12 companies in 15 trials: 11 Phase 2, 2 Phase 1, 1 Phase 3, 1 Phase 4; Oncology, Infectious disease; next expected readout Dec 2026.

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)

Open in Phaseline: the race on PDCD1LG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Second Affiliated Hospital of Chongqing Medical UniversityASC22
PD-L1 inhibitor
PDCD1LG1Phase 4Chronic Hepatitis bDec 2026
PfizerPF-08046054
Anti-PD-L1 antibody-drug conjugate
PDCD1LG1Phase 3Non-small Cell CarcinomaMar 2028
Chia Tai Tianqing Pharmaceutical GroupTQB2450 injection
humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1)
PDCD1LG1Phase 2Non Small Cell Lung CancerDec 2026
Shanghai Pulmonary Hospital, Shanghai, ChinaEnvolizumab
PD-L1 antibody
PDCD1LG1Phase 2Thymic CarcinomaDec 2026
Sir Run Run Shaw HospitalIcaritin
Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor
TNF, IL6, PDCD1LG1Phase 2Advanced Pancreatic Ductal AdenocarcinomaApr 2027
ImmunityBioPD-L1 t-haNK
PD-L1-targeted human aNK cell therapy
CD274, PDCD1LG1Phase 2Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck CancerMay 2027
Hebei Medical University Fourth HospitalAdebrelizumab
PD-L1 inhibitor
PDCD1LG1Phase 2Squamous Oesophageal CancerSep 2027
Hong QiuSHR-1701
Anti-PD-L1 monoclonal antibody
PDCD1LG1Phase 2CRC (Colorectal Cancer)Dec 2027
University Medical Center Groningen89Zr-atezolizumab PET-imaging
PD-L1 imaging with radiolabeled anti-PD-L1 antibody
PDCD1LG1Phase 2Large B-cell Lymphoma–
Yongxu JiaTQB2450
PD-L1 inhibitor (monoclonal antibody)
PDCD1LG1Phase 2Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma–
MediLink Therapeutics (Suzhou)Ivonescimab (AK112)
Bispecific antibody targeting PD-L1 and CTLA-4
PDCD1LG1, PDCD1LG2Phase 1Advanced Solid TumorsJan 2027
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyDCR-PDL1
PDL1 inhibitor delivered via RNAi
PDCD1LG1Phase 1Solid Tumors, AdultDec 2027

Conditions

Large B-cell Lymphoma (1) CRC (Colorectal Cancer) (1) Advanced Pancreatic Ductal Adenocarcinoma (1) Pancreatic Cancer (1) Non-Small Cell Lung Cancer (1) Glioblastoma (1) Head and Neck Cancer (1) Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (1) Solid Tumors, Adult (1) Non Small Cell Lung Cancer (1) Squamous Oesophageal Cancer (1) Non-small Cell Carcinoma (1)

Modalities

small molecule (6), mixed (3), antibody (1)

Companies

University Medical Center Groningen (1) Hong Qiu (1) Sir Run Run Shaw Hospital (1) ImmunityBio (1) Yongxu Jia (1) Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) Chia Tai Tianqing Pharmaceutical Group (1) Hebei Medical University Fourth Hospital (1) Pfizer (1) Shanghai Pulmonary Hospital, Shanghai, China (1) The Second Affiliated Hospital of Chongqing Medical University (1) MediLink Therapeutics (Suzhou) (1)

Related targets

TNF (1) IL6 (1) CD274 (1) PDCD1LG2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.